Press Releases Altimmune, Inc.

Equities

ALT

US02155H2004

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-02 pm EDT			5-day change	1st Jan Change
7.18 ^USD	+1.56%		+1.41%	-36.18%

Apr. 30	North American Morning Briefing : More Earnings -2-	DJ
Apr. 29	Altimmune Shares Decline After Guggenheim Downgrade	MT

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Altimmune to Report First Quarter 2024 Financial Results and Provide Business Update on May 9, 2024	May. 02	AQ
Altimmune to Participate at Two Upcoming Conferences	May. 01	AQ
Altimmune Statement on the Passing of Dr. Stephen Harrison	Apr. 25	AQ
Altimmune Announces Positive Lean Mass Preservation Data for Pemvidutide and Reports Fourth Quarter and Full Year 2023 Financial Results	Mar. 27	AQ
Altimmune to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on March 27, 2024	Mar. 20	AQ
ROSEN, A LONGSTANDING LAW FIRM, Encourages Altimmune, Inc. Investors to Inquire About Securities Class Action Investigation - ALT	Mar. 05	PR
Pomerantz Law Firm Investigates Claims on Behalf of Investors of Altimmune, Inc. - ALT	Mar. 03	PR
Altimmune, Inc. (ALT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings	Feb. 26	BU
Pomerantz Law Firm Investigates Claims on Behalf of Investors of Altimmune, Inc. - ALT	Feb. 24	PR
ROSEN, LEADING INVESTOR COUNSEL, Encourages Altimmune, Inc. Investors to Inquire About Securities Class Action Investigation - ALT	Feb. 16	PR
Pomerantz Law Firm Investigates Claims on Behalf of Investors of Altimmune, Inc. - ALT	Feb. 15	PR
ROSEN, A TOP RANKED LAW FIRM, Encourages Altimmune, Inc. Investors to Inquire About Securities Class Action Investigation – ALT	Feb. 14	BU
Altimmune Announces Presentation of Pemvidutide Clinical Data at Upcoming NASH-TAG Conference on January 6, 2024	Jan. 02	AQ
PRISM MarketView Highlights Altimmune's Positive Topline Results in Obesity Drug Trial	Dec. 06	AQ
Altimmune Announces Positive Topline Results from MOMENTUM 48-Week Phase 2 Obesity Trial of Pemvidutide	Nov. 30	AQ
Altimmune Announces Third Quarter 2023 Financial Results and Provides a Business Update	Nov. 07	AQ
Altimmune to Report Third Quarter 2023 Financial Results and Provide Business Update on November 7, 2023	23-10-31	AQ
Altimmune Granted Fast Track Designation by FDA for Pemvidutide for the Treatment of Non-Alcoholic Steatohepatitis	23-10-27	AQ
Altimmune to Present New Data on the Anti-Inflammatory and Anti-Fibrotic Properties of Pemvidutide in a Late-Breaking Presentation at the Liver Meeting 2023	23-10-26	AQ
Altimmune Granted Fast Track Designation by FDA for Pemvidutide for the Treatment of Non-Alcoholic Steatohepatitis (NASH)	23-10-26	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Altimmune, Inc.

Equities

ALT

US02155H2004

Press Releases

Filters